Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sihuan Pharma Acquires Beijing Combio, an Antibody/Bispecific Company

publication date: Jan 27, 2021

Sihuan Pharma will acquire Beijing Combio Pharma for an undisclosed price. An innovative biopharma, Combio is developing 12 preclinical molecules that it discovered using its two antibody platforms: Mab Edit (antibody editing) and Mebs-Ig (antibody editing for bispecific antibodies). Combio will become part of Sihuan's existing novel drug development company, Xuanzhu Biopharm. In August 2020, Xuanzhu raised $148 million in venture capital at a $700 million valuation. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.